

# Presentation Quarter 1, 2026

April 23, 2026



# Ulrika Kolsrud

President and CEO



# Highlights Q1 2026

- > Organic sales growth with higher volumes
- > Higher market shares in branded sales retail
- > Higher margins
- > Strong cash flow and balance sheet
- > New share buyback program
- > Feminine Care acquisition in North America completed

Organic sales growth

**+0.4%**  
of which  
volume **+1.1%**

EBITA excl. IAC

SEK  
**4,603m**  
**+5%<sup>1)</sup>**

<sup>1)</sup> Excluding currency translation effects

EBITA margin excl. IAC

**13.9%**  
**+40bps**

Operating cash flow

SEK  
**4,354m**  
**+16%**

# Health & Medical

- Growth in Medical Solutions with strong contribution from Wound Care and good growth in Orthopedics
- Weak sales quarter in Incontinence Products Health Care
- Strong growth in North America
- Upgrade of TENA assortment in North America
  - TENA ProSkin® Super Briefs
  - TENA ProSkin® Ultra Briefs



# Personal Care

- Higher market shares in >60% of branded sales
- Continued strong growth in Incontinence Products with high growth in Latin and North America
- High growth in Feminine Care with strong contribution from leakproof apparel
- Focus on integrating the Feminine Care acquisition in North America
- Launch of Libresse leakproof apparel specially designed for Teens
- Launch of softer baby diapers for Libero touch



# Consumer Tissue

- Sales decline, driven by lower sales in Europe
- Good growth in Latin America
- Higher market shares and volumes in branded sales
- First launch of coreless household towels – Zewa Wisch&Weg Smart
- New biomass boiler plant inaugurated in France



Le Theil, France



Kunheim, France

# Professional Hygiene

- Higher volumes with growth initiatives starting to pay off
- Stabilized market in North America
- Continued positive development of product mix with growth in strategic products
  - Tork PeakServe +10%
  - Skincare +5%




# Fredrik Rystedt

EVP and CFO




# Sales - positive contribution from volumes and M&A



<b>Organic sales growth:</b>	<b>+0.4%</b>
<b>Health &amp; Medical</b>	<b>+0.5%</b>
• Incontinence Health Care	-0.9%
• Medical Solutions	+2.5%
<b>Personal Care</b>	<b>+4.1%</b>
• Incontinence Retail	+5.1%
• Feminine Care	+5.6%
• Baby Care	-0.3%
<b>Consumer Tissue</b>	<b>-3.5%</b>
<b>Professional Hygiene</b>	<b>+1.9%</b>

# Higher margin with contribution from Health & Medical and Personal Care



**EBITA margin excl. IAC: 13.9%**

**Health & Medical** 18.4%


**Personal Care** 15.4%

**Consumer Tissue** 10.7%

**Professional Hygiene** 16.1%


# Continued strong operating cash flow

SEKbn




# Lower net debt and net debt vs EBITDA excl IAC of 1

SEKbn



# New share buyback program

- Essity B share buyback program of SEK 3bn
- Begins no earlier than May 11, 2026 and extends until AGM 2027 at the latest
- Safe Harbour compliant
- Ambition to use as a recurring part of Essity's capital allocation




# Ulrika Kolsrud

President and CEO




# Summary

- Q1 2026 – higher volumes and market shares, higher margins, M&A completed, new share buyback program, strong balance sheet
- Priorities 2026:
  - Grow market shares, supported by innovation across tiers
  - Successful integration of Feminine Care acquisition
  - Execute SG&A savings to invest in profitable growth and deliver COGS savings
  - Compensate higher input costs with price




# Essity breaks barriers on Earth and beyond

- Essity's JOBST® compression garments supported astronauts on **NASA's Artemis II Mission**
  - Compression garments help to manage the effects of significant fluid shifts experienced by the human body in microgravity environments
- JOBST® compression therapy solutions help people perform at their best: whether supporting those living with lymphedema, venous disease and other chronic conditions, or meeting the needs of astronauts in space!



Artemis II Mission launch  
(NASA/Bill Ingalls)



View of Earth taken by  
Artemis II Commander  
Reid Wiseman (NASA)



Artemis II Mission crew  
(NASA/Jim Ross)

This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.



# Q&A



# Essity's Capital Markets Day

May 7, 2026



Welcome to join  
in Gothenburg or virtually!

